ANVISA, Brazil problems 0 observations for Shilpa Medicare

ANVISA, Brazil problems 0 observations for Shilpa Medicare

by admin- Friday, August 25th, 2023 03:11:56 PM


Shilpa Medicare completed dosage form production facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana nation has gone through a GMP inspection by way of ANVISA, Brazil starting twenty first August 2023. The inspection has concluded correctly on twenty fourth Aug 2023 without any observations.

The facility is worried in manufacturing, packaging, labelling and trying out of finished dosage bureaucracy (sterile injections and non‐sterile oral solids) for the treatment of numerous varieties of cancer and adjuvant remedy.

This inspection is the 1/3 essential regulatory inspection (after Russia and Canada), cleared by means of this Site in the beyond two years.

This inspection and subsequent approval will allow the company for the economic distribution of products in Brazil marketplace and permit approval of recent packages for Brazil market.

The business enterprise remains devoted to hold the GMP fame and exceptional standards as in line with the expectations and requirements of Global Regulatory Authorities.

News Updates